Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Part of paid clinical trials in Walnut Creek, California.

Sponsor
Bay Area Retina Associates
Study ID
NCT03832179
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Key Dates

Start date
Nov 15, 2018
Status verified
Sep 2025
Primary completion
Sep 1, 2023
Completion
Mar 30, 2024

Study Design

Enrollment
16 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Anti-vascular endothelial growth factor
    Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
  • Experimental: Ozurdex
    Intravitreal Ozurdex

Primary Outcome Measure

Comparison of central foveal thickness outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy [ Time Frame: 3 months after cataract surgery ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bay Area Retina AssociatesWalnut CreekCalifornia94598-

Find similar trials in Walnut Creek, CA

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Bay Area Retina Associates· Walnut Creek, CA

Related Studies